Lexicon Pharmaceuticals, Inc. (LXRX) Forms $9.24 Double Bottom; Royce Micro-cap Trust (RMT) Sentiment Is 1.61

Lexicon Pharmaceuticals, Inc. (LXRX) formed double bottom with $8.69 target or 6.00% below today’s $9.24 share price. Lexicon Pharmaceuticals, Inc. (LXRX) has $975.63 million valuation. The stock decreased 0.54% or $0.05 during the last trading session, reaching $9.24. About 460,153 shares traded. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has risen 17.98% since February 13, 2017 and is uptrending. It has outperformed by 1.28% the S&P500.

Royce Micro-Cap Trust, Inc. is a closed-ended equity mutual fund launched and managed Royce & Associates, LLC. The company has market cap of $351.83 million. It invests in the public equity markets of the United States. It has a 5.08 P/E ratio. The fund seeks to invest in stocks of companies operating across diversified sectors.

The stock increased 0.33% or $0.03 during the last trading session, reaching $9.16. About 109,922 shares traded. Royce Micro-Cap Trust, Inc. (RMT) has risen 19.08% since February 13, 2017 and is uptrending. It has outperformed by 2.38% the S&P500.

Fiduciary Counselling Inc holds 3.78% of its portfolio in Royce Micro-Cap Trust, Inc. for 112,724 shares. Shaker Financial Services Llc owns 543,598 shares or 2.7% of their US portfolio. Moreover, Fca Corp Tx has 1.32% invested in the company for 341,561 shares. The Illinois-based Bard Associates Inc has invested 1.07% in the stock. Family Firm Inc., a Maryland-based fund reported 208,105 shares.

Among 9 analysts covering Lexicon Pharmaceuticals (NASDAQ:LXRX), 6 have Buy rating, 0 Sell and 3 Hold. Therefore 67% are positive. Lexicon Pharmaceuticals had 16 analyst reports since August 4, 2015 according to SRatingsIntel. Cowen & Co maintained Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) on Tuesday, August 1 with “Hold” rating. H.C. Wainwright initiated the stock with “Buy” rating in Friday, October 7 report. As per Monday, August 7, the company rating was maintained by Wedbush. Wedbush maintained the stock with “Buy” rating in Thursday, November 30 report. Wedbush maintained the stock with “Outperform” rating in Friday, August 5 report. The firm earned “Hold” rating on Monday, September 28 by Gabelli. The stock of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) has “Sell” rating given on Friday, September 18 by Gabelli. The firm has “Overweight” rating given on Monday, August 10 by JP Morgan. Citigroup initiated the shares of LXRX in report on Tuesday, August 2 with “Buy” rating. Stifel Nicolaus maintained it with “Buy” rating and $27.0 target in Friday, September 8 report.

Analysts await Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to report earnings on March, 2. They expect $-0.43 earnings per share, down 38.71% or $0.12 from last year’s $-0.31 per share. After $-0.29 actual earnings per share reported by Lexicon Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 48.28% negative EPS growth.